TAKEDA AGREES TO DIVEST SELECT OTC AND NON-CORE ASSETS TO ACINO FOR OVER $200 MILLION USD
New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection
SEE ALL NEWS AND RELEASES >
・For legacy Shire information, click here
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2019 Takeda Pharmaceutical Company Limited. All rights reserved.